AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Tango Therapeutics Inc. (TNGX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.44

0.03 (1.24%)

At close: Feb 20, 2025, 3:59 PM

2.43

-0.21%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	2.41
Market Cap	261.56M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.15
PE Ratio (ttm)	-2.12
Forward PE	n/a
Analyst	Buy

Ask	2.5
Volume	503,660
Avg. Volume (20D)	1,027,169
Open	2.43
Previous Close	2.41
Day's Range	2.42 - 2.51
52-Week Range	2.35 - 12.02
Beta	undefined

About TNGX

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 3, 2020

Employees 140

Stock Exchange NASDAQ

Ticker Symbol TNGX

Website https://www.tangotx.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for TNGX stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 433.88% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Tango Therapeutics Inc. is scheduled to release its earnings on Mar 17, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-37.45%

Tango Therapeutics shares are trading lower after ... Unlock content with Pro Subscription

11 months ago

-7.09%

Tango Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

News

4 weeks ago · seekingalpha.com

Tango Therapeutics: Chance For A Short Squeeze

Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Given the high short interest and the low number of shares outstanding, I expect a short squeeze ...

2 months ago · businesswire.com

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, toda...

2 months ago · businesswire.com

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference